Market reactionShares rose 16% on Nov 3.
Allarity Therapeutics is a clinical-stage company developing stenoparib, a PARP and WNT pathway inhibitor for ovarian cancer patients selected by its DRP test; it is not approved.
Allarity's case rests on DRP-selected stenoparib in platinum-resistant ovarian cancer. Phase 2 survival findings were strongest at the highest DRP scores; a pivotal design and funding remain the key gaps. Cash and restricted cash were $26.9 million at June 30, 2026; management expects funding into summer 2028. An Allarity subsidiary also sponsors a proposed $100 million SPAC. Allarity has terminated its Tumim share-sale agreement and plans alternative financing, making future funding terms important.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Cash lasts into summer 2028
Will replacement financing and planned spending support management's runway expectation while preserving resources for stenoparib?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Stenoparib awaits pivotal plan as Allarity drops Tumim agreement and seeks alternative financing
DRP-selected stenoparib chasing platinum-resistant ovarian cancer approval, funded to mid-2028 — pivotal data will confirm or refute the DRP selection thesis
Stenoparib's DRP-guided differentiation in platinum-resistant ovarian cancer hinges on Phase 2 data proving the companion diagnostic selects responders
Stenoparib's Phase 2 readout in platinum-resistant ovarian cancer will determine whether DRP-guided patient selection can unlock a viable path to pivotal approval
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Lung cancer, Breast and gynecologic cancers, Gastrointestinal cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
11 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.